Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a large decrease in short interest in June. As of June 30th, there was short interest totalling 193,000 shares, a decrease of 61.4% from the June 15th total of 500,300 shares. Currently, 1.2% of the company’s stock are sold short. Based on an average trading volume of 244,500 shares, the days-to-cover ratio is currently 0.8 days.

Gain Therapeutics Stock Performance

NASDAQ:GANX traded up $0.02 during mid-day trading on Friday, hitting $1.38. 270,476 shares of the company’s stock traded hands, compared to its average volume of 210,893. The firm has a 50 day moving average of $1.95 and a two-hundred day moving average of $3.19. Gain Therapeutics has a 12 month low of $1.11 and a 12 month high of $5.33. The firm has a market capitalization of $24.91 million, a price-to-earnings ratio of -0.92 and a beta of 0.35. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. On average, equities analysts forecast that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on GANX shares. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a research note on Tuesday, April 23rd. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday. Finally, Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Wednesday, March 27th.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.